Marker Therapeutics, Inc.MRKRNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank50
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-229.62%
↑ 98% vs avg
Percentile
P50
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-9879.48%
Historical baseline
PeriodValueYoY Change
TTM-229.62%-36.1%
2024-168.69%+52.6%
2023-356.14%+26.4%
2022-483.90%+84.5%
2021-3117.98%+47.3%
2020-5919.21%+43.7%
2019-10517.97%+85.4%
2018-71830.25%-1064.0%
2017-6171.07%-
20160.00%-